By BIOAGE LABS MARCH 21, 2022 A Phase 2 clinical trial is testing the new drug’s ability to reduce mortality in older people hospitalized with COVID-19. By directly targeting immune aging, BGE-175 could effectively treat emerging COVID variants that evade vaccine-based immunity. The immune system deteriorates with age, making COVID-19 particularly deadly in older people — but to date,...
